Based on the earnings transcript for Johnson & Johnson, the company reported solid financial results for 2011, with adjusted earnings per share of $5.05 to $5.15, excluding special items. The company also provided guidance for 2012, expecting sales to grow by 4% to 5% on a constant currency basis and earnings per share to grow by 3.5% to 5.5%. The company expects to continue to invest in its pipeline and innovation, and it is well-positioned to take advantage of opportunities in emerging markets. The company also expects to continue to face challenges in the medical device business, but it is optimistic about the future. Overall, the company's results and guidance suggest that it is well-positioned to continue to grow and deliver value to shareholders.